Clear Health Pass Holdings LLC develops and provides advanced in-vitro diagnostic testing solutions, including saliva and fecal-based health diagnostic collections, genomics, and medical wellness testing. The company serves medical facilities, businesses, and government entities with diagnostic tools spanning areas such as cardiology, diabetes, genetics, women's health, allergies, and drug screening.
Subscribe to see Clear Health Pass Holdings LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Clear Health Pass Holdings LLC is a healthcare diagnostics company headquartered in New York, United States. Its most recent funding round raised $100M in September 2021. Xcout tracks 1 named person at Clear Health Pass Holdings LLC, including John Cataldi (CEO).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $100M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Clear Health Pass Holdings LLC's closest competitors — see the full list of competitors and alternatives →
Incite Health Life Sciences, Inc. is a CLIA-certified and CAP-accredited high-complexity clinical laboratory that provides specialized diagnostic testing, including pharmacogenomics, infectious disease screening, and immune system monitoring. The company serves physicians, medical institutions, employers, and clinical trials by utilizing advanced methodologies and data-driven approaches to support early detection, disease monitoring, and personalized medicine.
Helix Holdings I, LLC provides a population genomics and clinical testing platform that delivers genetic insights and infrastructure for patients, providers, health systems, and life sciences organizations. The company offers solutions for clinical test ordering, population health programs, and a clinico-genomic database used for research, drug discovery, and clinical trials.
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Access Genetics LLC operates a national reference laboratory that provides personalized diagnostics and molecular DNA testing services, including salivary diagnostics through its OralDNA Labs division. The company serves healthcare clients and patients by offering comprehensive diagnostic test options and clinical lab services.
Nightingale Health Plc provides advanced health check and remote health check products designed for the healthcare, insurance, government, and consumer health sectors. The company also offers proprietary 'omics technology and preventive screening solutions to support medical research and disease risk detection.
EBIEN Inc. operates a CLIA-certified clinical laboratory that provides advanced diagnostic testing services to healthcare providers, wellness clinics, and organizations. The company offers hormone, metabolic, nutritional, and genetic testing panels along with private-label solutions and educational resources to support personalized clinical care.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Clear Health Pass Holdings LLC? Suggest a correction · Work at Clear Health Pass Holdings LLC? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.